FcγRIIIa (CD16) induction on human t lymphocytes and CD16pos T-lymphocyte amplification

Journal of Immunotherapy

Volumn 34, Issue 7, 2011, Pages 542-549

  Clémenceau, Béatrice ^a,b   Vivien, Régine ^a   Debeaupuis, Emilie ^a,b   Esbelin, Julie ^a,b   Biron, Charlotte ^a,b   Levy, Yves ^c   Vié, Henri ^a,b  

^a UNIVERSITÉ DE NANTES   (France)

^b NANTES UNIVERSITY HOSPITAL   (France)

^c INSERM U955   (France)

Author keywords

ADCC; CD16; Fc RIIIa; induction; T lymphocytes

Indexed keywords

CD16 ANTIGEN; INTERLEUKIN 2; T LYMPHOCYTE RECEPTOR ALPHA CHAIN; T LYMPHOCYTE RECEPTOR BETA CHAIN;

ANTIBODY DEPENDENT CELLULAR CYTOTOXICITY; ARTICLE; CELL EXPANSION; CELL PROLIFERATION; CELL SELECTION; CONTROLLED STUDY; CYTOTOXICITY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN TISSUE; NATURAL KILLER CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; T LYMPHOCYTE; UMBILICAL CORD BLOOD;

ANTIGENS, CD3; CD8-POSITIVE T-LYMPHOCYTES; CELL PROLIFERATION; CELLS, CULTURED; FETAL BLOOD; FLOW CYTOMETRY; GPI-LINKED PROTEINS; HERPESVIRUS 4, HUMAN; HIV INFECTIONS; HUMANS; KILLER CELLS, NATURAL; LEUKOCYTES, MONONUCLEAR; LYMPHOCYTE ACTIVATION; RECEPTORS, ANTIGEN, T-CELL, ALPHA-BETA; RECEPTORS, IGG;

EID: 80051549961     PISSN: 15249557     EISSN: 15374513     Source Type: Journal    
DOI: 10.1097/CJI.0b013e31822801d4     Document Type: Article

References (29)

1. Therasse P. Measuring the clinical response. What does it mean? Eur J Cancer. 2002;38:1817-1823. (Pubitemid 35256090)
2. Izumi Y, Xu L, di Tomaso E, et al. Tumour biology: herceptin acts as an anti-angiogenic cocktail. Nature. 2002;416:279-280. (Pubitemid 34260234)
3. Clynes RA, Towers TL, Presta LG, et al. Inhibitory Fc receptors modulate in vivo cytoxicity against tumor targets. Nat Med. 2000;6:443-446. (Pubitemid 30208162)
4. Gennari R, Menard S, Fagnoni F, et al. Pilot study of the mechanism of action of preoperative trastuzumab in patients with primary operable breast tumors overexpressing HER2. Clin Cancer Res. 2004;10:5650-5655. (Pubitemid 39180938)
5. Sliwkowski MX, Lofgren JA, Lewis GD, et al. Nonclinical studies addressing the mechanism of action of trastuzumab (Herceptin). Semin Oncol. 1999;26:60-70. (Pubitemid 29411434)
6. Tokuda Y, Ohnishi Y, Shimamura K, et al. In vitro and in vivo anti-tumour effects of a humanised monoclonal antibody against c-erbB-2 product. Br J Cancer. 1996;73:1362-1365. (Pubitemid 26175668)
7. Cartron G, Dacheux L, Salles G, et al. Therapeutic activity of humanized anti-CD20 monoclonal antibody and polymorphism in IgG Fc receptor FcgammaRIIIa gene. Blood. 2002;99:754-758. (Pubitemid 34525533)
8. Koene HR, Kleijer M, Algra J, et al. Fc gammaRIIIa-158V/F polymorphism influences the binding of IgG by natural killer cell Fc gammaRIIIa, independently of the Fc gammaRIIIa-48L/R/H phenotype. Blood. 1997;90:1109-1114. (Pubitemid 27314146)
9. Iannello A, Ahmad A. Role of antibody-dependent cell-mediated cytotoxicity in the efficacy of therapeutic anti-cancer monoclonal antibodies. Cancer Metastasis Rev. 2005;24:487-499. (Pubitemid 43096997)
10. Lejeune J, Thibault G, Cartron G, et al. Implications of receptors for the Fc portion of IgG (FcgammaRs) in mechanism of action of therapeutic antibodies. Bull Cancer. 2010;97:511-522.
11. Ravetch JV, Bolland S. IgG Fc receptors. Annu Rev Immunol. 2001;19:275-290. (Pubitemid 32368037)
12. Lanier LL, Kipps TJ, Phillips JH. Functional properties of a unique subset of cytotoxic CD3+ T lymphocytes that express Fc receptors for IgG (CD16/Leu-11 antigen). J Exp Med. 1985;162:2089-2106. (Pubitemid 16149696)
13. Drugarin D, Tatu C, Noveanu L, et al. Identification of a novel subset of T lymphocytes in patients with Balkanic nephropathy. Autoimmunity. 1996;23:119-126. (Pubitemid 26335867)
14. Drugarin D, Bona CA, Noveanu L, et al. CD3+, CD16+, CD56+ cells: a novel subset of T lymphocytes from patients with Balkanic nephropathy. Roum Arch Microbiol Immunol. 1995;54:255-264.
15. Clemenceau B, Vivien R, Berthome M, et al. Effector memory alphabeta T lymphocytes can express FcgammaRIIIa and mediate antibody-dependent cellular cytotoxicity. J Immunol. 2008;180:5327-5334.
16. Bjorkstrom NK, Gonzalez VD, Malmberg KJ, et al. Elevated numbers of Fc gamma RIIIA+ (CD16+) effector CD8 T cells with NK cell-like function in chronic hepatitis C virus infection. J Immunol. 2008;181:4219-4228.
17. Angelini DF, Borsellino G, Poupot M, et al. FcgammaRIII discriminates between 2 subsets of Vgamma9Vdelta2 effector cells with different responses and activation pathways. Blood. 2004;104:1801-1807. (Pubitemid 39202290)
18. Braakman E, van de Winkel JG, van Krimpen BA, et al. CD16 on human gamma delta T lymphocytes: expression, function, and specificity for mouse IgG isotypes. Cell Immunol. 1992; 143:97-107.
19. Clemenceau B, Congy-Jolivet N, Gallot G, et al. Antibodydependent cellular cytotoxicity (ADCC) is mediated by genetically modified antigen-specific human T lymphocytes. Blood. 2006;107:4669-4677. (Pubitemid 43882614)
20. Clemenceau B, Gallot G, Vivien R, et al. Long-term preservation of antibody-dependent cellular cytotoxicity (ADCC) of natural killer cells amplified in vitro from the peripheral blood of breast cancer patients after chemotherapy. J Immunother. 2006;29:53-60.
21. Abedin S, Michel JJ, Lemster B, et al. Diversity of NKR expression in aging T cells and in T cells of the aged: the new frontier into the exploration of protective immunity in the elderly. Exp Gerontol. 2005;40:537-548. (Pubitemid 41074799)
22. Rickinson AB, Moss DJ, Allen DJ, et al. Reactivation of Epstein-Barr virus-specific cytotoxic T cells by in vitro stimulation with the autologous lymphoblastoid cell line. Int J Cancer. 1981;27:593-601. (Pubitemid 11101744)
23. Smith CA, Ng CY, Heslop HE, et al. Production of genetically modified Epstein-Barr virus-specific cytotoxic T cells for adoptive transfer to patients at high risk of EBV-associated lymphoproliferative disease. J Hematother. 1995;4:73-79.
24. Ibisch C, Saulquin X, Gallot G, et al. The T cell repertoire selected in vitro against EBV: diversity, specificity, and improved purification through early IL-2 receptor alpha-chain (CD25)-positive selection. J Immunol. 2000;164:4924-4932. (Pubitemid 30238098)
25. Perussia B, Ramoni C, Anegon I, et al. Preferential proliferation of natural killer cells among peripheral blood mononuclear cells cocultured with B lymphoblastoid cell lines. Nat Immun Cell Growth Regul. 1987;6:171-188. (Pubitemid 18083744)
26. Zupo S, Azzoni L, Massara R, et al. Coexpression of Fc gamma receptor IIIA and interleukin-2 receptor beta chain by a subset of human CD3+/CD8+/CD11b+ lymphocytes. J Clin Immunol. 1993;13:228-236. (Pubitemid 23151228)
27. Uciechowski P, Werfel T, Leo R, et al. Analysis of CD16+dim and CD16+bright lymphocytes-comparison of peripheral and clonal non-MHC-restricted T cells and NK cells. Immunobiology. 1992;185:28-40.
28. Roederer M, Dubs JG, Anderson MT, et al. CD8 naive T cell counts decrease progressively in HIV-infected adults. J Clin Invest. 1995;95:2061-2066.
29. Chen G, Shankar P, Lange C, et al. CD8 T cells specific for human immunodeficiency virus, Epstein-Barr virus, and cytomegalovirus lack molecules for homing to lymphoid sites of infection. Blood. 2001;98:156-164.